AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23073143 — intervention group
Group type: EXPERIMENTAL
Intervention: 100-mg sarpogrelate IR 3 times at a 6-h interval
Number of subjects: 36
Study 23073143 — intervention group
Group type: COMPARATOR
Intervention: 300-mg sarpogrelate CR once
Number of subjects: 36
Study 23073143 — intervention group
Group type: COMPARATOR
Intervention: CR formulation
Number of subjects: 36
Study 23073143 — intervention group
Group type: EXPERIMENTAL
Intervention: IR formulation
Number of subjects: 36
Study 20624624 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg for 7 days before surgery
Number of subjects: 104
Study 20624624 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 10 mg for 7 days before surgery
Number of subjects: 104
Study 19301514 — intervention group
Group type: EXPERIMENTAL
Intervention: Test Dentifrice (0.3% triclosan/2.0% PVM/MA copolymer/0.243% sodium fluoride in a 17% dual silica base)
Number of subjects: 94
Study 19301514 — intervention group
Group type: COMPARATOR
Intervention: Control Dentifrice (0.243% sodium fluoride in a silica base)
Number of subjects: 94
Study 17147088 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium Phosphate 40 milliliters the day before and the day of colonoscopy
Number of subjects: 273
Study 17147088 — intervention group
Group type: EXPERIMENTAL
Intervention: Senna 12 mg and Magnesium Sulphate 15 mg the day before colonoscopy
Number of subjects: 273
Study 17147088 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyethylene Glycol-based solution of two litres plus 4 tablets of Bisacodyl the day before the exam
Number of subjects: 273
Study 12681033 — intervention group
Group type: EXPERIMENTAL
Intervention: GyneFix
Number of subjects: 175
Study 12681033 — intervention group
Group type: COMPARATOR
Intervention: Gyne-T380S
Number of subjects: 175
Study 10720544 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF; 0.3 mg/mL 3 times a week) for 12 weeks
Number of subjects: 30
Study 9192400 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition and eating‐habit change followed by exercise (NE)
Number of subjects: 0
Study 9192400 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise followed by nutrition and eating‐habit change (EN)
Number of subjects: 0
Study 9192400 — intervention group
Group type: COMPARATOR
Intervention: Information control (INFO)
Number of subjects: 0
Study 1337322 — intervention group
Group type: COMPARATOR
Intervention: Molsidomine (16 mg)
Number of subjects: 12
Study 1337322 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 3990295 — intervention group
Group type: EXPERIMENTAL
Intervention: Expected alcohol consumption during low-attention demand task
Number of subjects: 32
Study 3990295 — intervention group
Group type: EXPERIMENTAL
Intervention: Actual alcohol consumption during high-attention demand task
Number of subjects: 32
Study 3990295 — intervention group
Group type: COMPARATOR
Intervention: Sober condition during both cognitive tasks
Number of subjects: 32
Study 31256126 — intervention group
Group type: EXPERIMENTAL
Intervention: D‐CHESS (Dementia‐Comprehensive Health Enhancement Support System) for 6 months
Number of subjects: 31
Study 31256126 — intervention group
Group type: COMPARATOR
Intervention: Caregiving book (Control)
Number of subjects: 31
Study 29889245 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 min Brief Advice
Number of subjects: 205
Study 29889245 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Advice plus 20 min of brief Counselling
Number of subjects: 205
Study 29889245 — intervention group
Group type: COMPARATOR
Intervention: Screening only (Controls)
Number of subjects: 205
Study 29889245 — intervention group
Group type: EXPERIMENTAL
Intervention: Routinely collected re-offending data
Number of subjects: 205
Study 29889245 — intervention group
Group type: EXPERIMENTAL
Intervention: Indices of deprivation data
Number of subjects: 205
Study 27317303 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan
Number of subjects: 50
Study 27317303 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CsA)
Number of subjects: 50
Study 27317303 — intervention group
Group type: EXPERIMENTAL
Intervention: VIVIT
Number of subjects: 50
Study 27317303 — intervention group
Group type: EXPERIMENTAL
Intervention: 4‐aminopyridine (4‐AP)
Number of subjects: 50
Study 27317303 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 50
Study 24773615 — intervention group
Group type: EXPERIMENTAL
Intervention: Tribulus terrestris extract (7.5 mg/day)
Number of subjects: 67
Study 24773615 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 23021433 — intervention group
Group type: COMPARATOR
Intervention: Daily oral glutamine (0.5 g kg(‐1) d(‐1)) for 4 months
Number of subjects: 30
Study 23021433 — intervention group
Group type: COMPARATOR
Intervention: Acute oral glutamine (0.5 g kg(‐1) d(‐1)) for 5 hours
Number of subjects: 30
Study 19908093 — intervention group
Group type: EXPERIMENTAL
Intervention: TACE with DC Bead loaded with doxorubicin
Number of subjects: 212
Study 19908093 — intervention group
Group type: COMPARATOR
Intervention: cTACE with doxorubicin
Number of subjects: 212
Study 19908093 — intervention group
Group type: EXPERIMENTAL
Intervention: TACE with DC Bead
Number of subjects: 212
Study 18505468 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (ET) for 3 months
Number of subjects: 124
Study 18505468 — intervention group
Group type: COMPARATOR
Intervention: Control group (untrained)
Number of subjects: 124
Study 16054408 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain prevalence among women
Number of subjects: 3616
Study 16054408 — intervention group
Group type: EXPERIMENTAL
Intervention: Socio-economic factors (e.g. financial strain)
Number of subjects: 3616
Study 16054408 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial work conditions (i.e. work strain and social support)
Number of subjects: 3616
Study 16054408 — intervention group
Group type: EXPERIMENTAL
Intervention: Socio-economic/psychosocial work conditions
Number of subjects: 3616
Study 12848286 — intervention group
Group type: EXPERIMENTAL
Intervention: High-DHA eggs (135 mg DHA/egg)
Number of subjects: 0
Study 12848286 — intervention group
Group type: COMPARATOR
Intervention: Ordinary eggs (18 mg DHA/egg)
Number of subjects: 0
Study 12848286 — intervention group
Group type: EXPERIMENTAL
Intervention: High-DHA eggs
Number of subjects: 0
Study 12848286 — intervention group
Group type: COMPARATOR
Intervention: Ordinary eggs
Number of subjects: 0
Study 11200150 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan and 5-FU/leucovorin
Number of subjects: 0
Study 11200150 — intervention group
Group type: COMPARATOR
Intervention: 5-FU/leucovorin
Number of subjects: 0
Study 9004188 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-segment absorption model for diclofenac sodium
Number of subjects: 0
Study 9004188 — intervention group
Group type: COMPARATOR
Intervention: Conventional pharmacokinetic method (first-order absorption)
Number of subjects: 0
Study 9004188 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-segment absorption models
Number of subjects: 0
Study 1480873 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual treatment of pelvic joint dysfunction
Number of subjects: 39
Study 1480873 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment (massage)
Number of subjects: 39
Study 3758947 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine (0.6 microgram) + Hepatitis B immune globulin (500 IU)
Number of subjects: 175
Study 3758947 — intervention group
Group type: COMPARATOR
Intervention: Hepatitis B vaccine only (0.6 microgram)
Number of subjects: 175
Study 3758947 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster inoculation (0.6 microgram)
Number of subjects: 175
Study 29308823 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-propelled particles (SPPs) with a constant force f
Number of subjects: 0
Study 27803230 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous radiofrequency heat lesion (80oC during 60 seconds per level) applied to the medial branch of the primary dorsal ramus
Number of subjects: 60
Study 27803230 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure (same procedure without the radiofrequency lesion)
Number of subjects: 60
Study 27803230 — intervention group
Group type: EXPERIMENTAL
Intervention: Graded activity physiotherapy programme (both groups received this)
Number of subjects: 60
Study 24849077 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (self-measurement of pressure pain sensitivity followed by acupressure)
Number of subjects: 213
Study 24849077 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 213
Study 22273342 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led cognitive behavioral group therapy once a week for 12 weeks
Number of subjects: 41
Study 22273342 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led cognitive behavioral group therapy
Number of subjects: 41
Study 20382983 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular repair
Number of subjects: 1252
Study 20382983 — intervention group
Group type: COMPARATOR
Intervention: Open repair
Number of subjects: 1252
Study 17888042 — intervention group
Group type: EXPERIMENTAL
Intervention: Cystoscopic surveillance (CUS)
Number of subjects: 220
Study 17888042 — intervention group
Group type: COMPARATOR
Intervention: Microsatellite analysis (MA)
Number of subjects: 220
Study 16015266 — intervention group
Group type: EXPERIMENTAL
Intervention: MN‐1 (n = 360)
Number of subjects: 2100
Study 16015266 — intervention group
Group type: EXPERIMENTAL
Intervention: MN‐2 (n = 374)
Number of subjects: 2100
Study 16015266 — intervention group
Group type: COMPARATOR
Intervention: Control (n = 366)
Number of subjects: 2100
Study 16015266 — intervention group
Group type: EXPERIMENTAL
Intervention: MN‐1
Number of subjects: 2100
Study 16015266 — intervention group
Group type: EXPERIMENTAL
Intervention: MN‐2
Number of subjects: 2100
Study 16015266 — intervention group
Group type: EXPERIMENTAL
Intervention: MN‐2 among anaemic women (30%)
Number of subjects: 2100
Study 16015266 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 2100
Study 12534609 — intervention group
Group type: EXPERIMENTAL
Intervention: Valaciclovir 500 mg
Number of subjects: 249
Study 12534609 — intervention group
Group type: EXPERIMENTAL
Intervention: Valaciclovir 1000 mg
Number of subjects: 249
Study 12534609 — intervention group
Group type: EXPERIMENTAL
Intervention: Valaciclovir 2000 mg
Number of subjects: 249
Study 12534609 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 249
Study 10085416 — intervention group
Group type: EXPERIMENTAL
Intervention: RT-PCR for PSA
Number of subjects: 106
Study 10085416 — intervention group
Group type: EXPERIMENTAL
Intervention: RT-PCR for PSMA
Number of subjects: 106
Study 10085416 — intervention group
Group type: EXPERIMENTAL
Intervention: RT-PCR for Tyrosinase
Number of subjects: 106
Study 7828385 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg lifibrol for 4 weeks
Number of subjects: 491
Study 7828385 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg lifibrol for 4 weeks
Number of subjects: 491
Study 7828385 — intervention group
Group type: EXPERIMENTAL
Intervention: 450 mg lifibrol for 4 weeks
Number of subjects: 491
Study 7828385 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg lifibrol for 4 weeks
Number of subjects: 491
Study 7828385 — intervention group
Group type: EXPERIMENTAL
Intervention: 900 mg lifibrol for 4 weeks
Number of subjects: 491
Study 7828385 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg lifibrol for 12 weeks
Number of subjects: 491
Study 7828385 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg lifibrol for 12 weeks
Number of subjects: 491
Study 7828385 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg lifibrol for 12 weeks
Number of subjects: 491
Study 7828385 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 491
Study 2193858 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural steroid administration (50 mg Ultracortene‐H) with 2 mg morphine hydrochloride
Number of subjects: 95
Study 2193858 — intervention group
Group type: COMPARATOR
Intervention: Epidural morphine hydrochloride without Ultracortene‐H
Number of subjects: 95
Study 869108 — intervention group
Group type: EXPERIMENTAL
Intervention: Furazolidone
Number of subjects: 172
Study 869108 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimorazole
Number of subjects: 172
Study 869108 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole
Number of subjects: 172
Study 869108 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinidazole
Number of subjects: 172
Study 869108 — intervention group
Group type: COMPARATOR
Intervention: Control group (no medication)
Number of subjects: 172
Study 31825554 — intervention group
Group type: EXPERIMENTAL
Intervention: Mannitol
Number of subjects: 70
Study 31825554 — intervention group
Group type: COMPARATOR
Intervention: PEG
Number of subjects: 70
Study 30952223 — intervention group
Group type: EXPERIMENTAL
Intervention: Low SWAT + 25 Epoch SIOO
Number of subjects: 33
Study 30952223 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher SWAT and lower SIOO
Number of subjects: 33
Study 28682681 — intervention group
Group type: EXPERIMENTAL
Intervention: T-DM1
Number of subjects: 375
Study 28682681 — intervention group
Group type: EXPERIMENTAL
Intervention: T-DM1 with ET
Number of subjects: 375
Study 28682681 — intervention group
Group type: COMPARATOR
Intervention: Trastuzumab with ET
Number of subjects: 375
Study 28682681 — intervention group
Group type: EXPERIMENTAL
Intervention: Early responders
Number of subjects: 375
Study 24754379 — intervention group
Group type: EXPERIMENTAL
Intervention: TDT 068
Number of subjects: 61
Study 24754379 — intervention group
Group type: COMPARATOR
Intervention: Vehicle gel (control)
Number of subjects: 61
Study 23662047 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan plus Azelnidipine (16 mg/day)
Number of subjects: 52
Study 23662047 — intervention group
Group type: COMPARATOR
Intervention: Olmesartan plus Amlodipine (5 mg/day)
Number of subjects: 52
Study 21566261 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg DHEA once daily
Number of subjects: 125
Study 21566261 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study 17698861 — intervention group
Group type: EXPERIMENTAL
Intervention: Bispectral Index (BIS) monitor with cut off values of 85, 70, and 55
Number of subjects: 85
Study 16874601 — intervention group
Group type: EXPERIMENTAL
Intervention: Kangaroo Care (KC)
Number of subjects: 78
Study 16874601 — intervention group
Group type: COMPARATOR
Intervention: Radiant Warmers (Control)
Number of subjects: 78
Study 12641863 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 0
Study 10980214 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosinopril 20 mg/day
Number of subjects: 864
Study 10980214 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg/day
Number of subjects: 864
Study 10980214 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosinopril 20 mg/day and Pravastatin 40 mg/day
Number of subjects: 864
Study 10980214 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 864
Study 9380271 — intervention group
Group type: EXPERIMENTAL
Intervention: OB-R immunoreactivity in the brain
Number of subjects: 35
Study 9380271 — intervention group
Group type: EXPERIMENTAL
Intervention: Western blotting analysis
Number of subjects: 35
Study 9380271 — intervention group
Group type: COMPARATOR
Intervention: Comparison among groups (lean, obese, diabetic)
Number of subjects: 35
Study 8407737 — intervention group
Group type: EXPERIMENTAL
Intervention: Revised package insert instructions (PII)
Number of subjects: 20
Study 8407737 — intervention group
Group type: COMPARATOR
Intervention: Original package insert instructions (PII)
Number of subjects: 20
Study 8407737 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants' perception of device usability
Number of subjects: 20
Study 3490077 — intervention group
Group type: EXPERIMENTAL
Intervention: Periurethral injections of 10 ml 0.25% Bupivacaine, administered three times in 2-week intervals.
Number of subjects: 50
Study 3490077 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute maximum functional electrostimulation (AMFES) by vaginal electrode.
Number of subjects: 50
Study 28339166 — intervention group
Group type: EXPERIMENTAL
Intervention: Avatrombopag; single doses under fasted and fed conditions.
Number of subjects: 0
Study 28339166 — intervention group
Group type: EXPERIMENTAL
Intervention: Avatrombopag; single dose.
Number of subjects: 0
Study 28339166 — intervention group
Group type: COMPARATOR
Intervention: Avatrombopag; comparison between Japanese and white subjects.
Number of subjects: 0
Study 28339166 — intervention group
Group type: EXPERIMENTAL
Intervention: Avatrombopag; general administration.
Number of subjects: 0
Study 26981792 — intervention group
Group type: EXPERIMENTAL
Intervention: Double gloves
Number of subjects: 1536
Study 26981792 — intervention group
Group type: COMPARATOR
Intervention: Single gloves
Number of subjects: 1536
Study 26981792 — intervention group
Group type: COMPARATOR
Intervention: Unused control gloves
Number of subjects: 1536
Study 26981792 — intervention group
Group type: EXPERIMENTAL
Intervention: Double gloves (total analysis)
Number of subjects: 1536
Study 26981792 — intervention group
Group type: EXPERIMENTAL
Intervention: Inner gloves from double set
Number of subjects: 1536
Study 26981792 — intervention group
Group type: EXPERIMENTAL
Intervention: Double gloves protection
Number of subjects: 1536
Study 24710562 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended care (EC) - fortnightly telephone counselling from a dietitian and exercise physiologist up to 100 days post transplantation
Number of subjects: 37
Study 24710562 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended care (EC)
Number of subjects: 37
Study 24710562 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 37
Study 24710562 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 37
Study 22474954 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ointment prepared from Morinda citrifolia stem extract
Number of subjects: 40
Study 22474954 — intervention group
Group type: EXPERIMENTAL
Intervention: Morindicone and morinthone isolated from the extract
Number of subjects: 40
Study 20837589 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulant monotherapy optimization with methylphenidate preparation (once-daily, triphasic release) and behavioral therapy
Number of subjects: 65
Study 20837589 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulant monotherapy
Number of subjects: 65
Study 18394875 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol/fluticasone propionate combination (SFC) 50microg/250microg + 1 placebo tablet
Number of subjects: 383
Study 18394875 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone propionate 250microg + 1 sustained release theophylline 200mg (SR-T+FP)
Number of subjects: 383
Study 18394875 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol/fluticasone propionate combination (SFC)
Number of subjects: 383
Study 18394875 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 383
Study 15944972 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous platelet-rich plasma (PRP)
Number of subjects: 18
Study 15944972 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 18
Study 12459668 — intervention group
Group type: COMPARATOR
Intervention: Conventional mechanical ventilation (control)
Number of subjects: 0
Study 12459668 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung-protective strategy
Number of subjects: 0
Study 12459668 — intervention group
Group type: COMPARATOR
Intervention: Both groups (entry)
Number of subjects: 0
Study 12459668 — intervention group
Group type: COMPARATOR
Intervention: Both groups (36 hours)
Number of subjects: 0
Study 10365356 — intervention group
Group type: EXPERIMENTAL
Intervention: Griffiths mental scales assessment for VLBW infants
Number of subjects: 150
Study 10365356 — intervention group
Group type: COMPARATOR
Intervention: Control group of 60 infants assessed at a primary health care clinic
Number of subjects: 150
Study 10365356 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual impairment assessment
Number of subjects: 150
Study 10365356 — intervention group
Group type: EXPERIMENTAL
Intervention: Hearing impairment assessment
Number of subjects: 150
Study 10365356 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebral palsy assessment
Number of subjects: 150
Study 10365356 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional handicap assessment
Number of subjects: 150
Study 7706786 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic verotoxin (VT, shiga‐like toxin) Pk‐trisaccharide receptor sequences attached to Chromosorb (Synsorb‐Pk)
Number of subjects: 0
Study 7706786 — intervention group
Group type: EXPERIMENTAL
Intervention: Synsorb‐Pk
Number of subjects: 0
Study 7706786 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 0
Study 1980979 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic detergent preparation of pH 5.5
Number of subjects: 0
Study 1980979 — intervention group
Group type: COMPARATOR
Intervention: Synthetic detergent preparation of pH 7.0
Number of subjects: 0
Study 7234652 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin therapy
Number of subjects: 58
Study 7234652 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin therapy
Number of subjects: 58
Study 7234652 — intervention group
Group type: COMPARATOR
Intervention: No treatment or minor analgesic therapy
Number of subjects: 58
Study 7234652 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin and Indomethacin
Number of subjects: 58
Study 30621789 — intervention group
Group type: EXPERIMENTAL
Intervention: Preconception lifestyle intervention
Number of subjects: 577
Study 30621789 — intervention group
Group type: EXPERIMENTAL
Intervention: Preconception lifestyle intervention (successful weight loss)
Number of subjects: 577
Study 30621789 — intervention group
Group type: COMPARATOR
Intervention: Control group (prompt infertility treatment)
Number of subjects: 577
Study 29972245 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy autogenous tooth roots (TR)
Number of subjects: 30
Study 29972245 — intervention group
Group type: COMPARATOR
Intervention: Cortical autogenous bone blocks (AB)
Number of subjects: 30
Study 27254026 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (Cisplatin and 5-fluorouracil)
Number of subjects: 31